Clinical approach to lymphadenopathy.

Gerassimos A. Pangalis(Athens Medical Center), P Fessas, Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), T. P. Vassilakopoulos

PubMed

December 1, 1993

Cited by 93

Related Papers

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

|Nature Immunology|2001|3k

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

|New England Journal of Medicine|2016|1.4k

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

|Nature Communications|2015|1.2k

Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation

|Science|1993|914

The complex role of tumor-infiltrating macrophages

|Nature Immunology|2022|859